TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Trial Profile

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGER-2
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 16 Mar 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
    • 07 Dec 2016 Results of biomarker stratification of outcomes data from two studies (TIGER-X and TIGER-2) presented at the 17th World Conference on Lung Cancer
    • 07 Jun 2016 Results (n=115) from this trial and other trial (TIGER-X) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top